Skip to main content

ORTHOFIX International N V Value Stock - Dividend - Research Selection

Orthofix international n v

ISIN: US68752M1080 , WKN: A2NB0X

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!

How our site works ...

✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month 
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Orthofix International N.V., a medical device company, provides musculoskeletal healing products and value-added services worldwide. It operates through four segments: BioStim, Extremity Fixation, Spine Fixation, and Biologics. The BioStim segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion and are indicated as treatment to enhance fusion success rates in cervical and lumbar spine, as well as a therapeutic treatment for non-spine fractures. The Extremity Fixation segment designs, develops, and markets orthopedic products used in fracture repair, deformity correction, and bone reconstruction procedures. The Spine Fixation segment designs, develops, and markets a portfolio of implant products used in surgical procedures of the spine. The Biologics segment provides a portfolio of regenerative products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. Orthofix International N.V. was founded in 1987 and is headquartered in Lewisville, Texas.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Orthofix Medical (OFIX) Stock Sees Fair Value Cut After Analysts Trim Q2 Outlook

2026-08-24
Orthofix Medical recently saw its analyst price target move from US$15 to US$13, a reset that anchors the latest round of valuation work on the stock. Analysts link this change to updated views on revenue, cash generation and the impact of the MDR transition, even as many maintain a constructive long-term stance. Read on to see what is driving the shift in targets and how you can track the evolving Orthofix Medical story from here. Analyst Price Targets don't always capture the full story...

Orthofix Medical Sees Reimbursement Rebound, but Spine Slump Clouds Outlook

2026-08-16
Orthofix Medical (NASDAQ:OFIX) executives said the company’s updated outlook reflects the restoration of bone growth stimulation reimbursement, improving trends in biologics and limb reconstruction, and an expected European inventory order, partly offset by a steeper-than-anticipated decline among s

Orthofix (OFIX) Q2 2026 Earnings Call Transcript

2026-08-12
Biologics stabilize while spine fixation grows double-digit internationally.

Canaccord Genuity Maintains Buy on Orthofix Medical, Lowers Price Target to $13

2026-08-10
Canaccord Genuity analyst Caitlin Burrows maintains Orthofix Medical (NASDAQ:OFIX) with a Buy and lowers the price target from $18 to $13.

Orthofix Medical Inc (OFIX) (Q2 2026) Earnings Call Highlights: Strategic Moves and Raised ...

2026-08-05
Orthofix Medical Inc (OFIX) delivers 5% pro forma growth, raises EBITDA guidance, and navigates a complex landscape of European MDR opportunities and U.S. distributor headwinds.

Orthofix Medical Q2 Earnings Call Highlights

2026-08-05
Orthofix Medical (NASDAQ:OFIX) reported second-quarter results that management said reflected improving operating trends across several businesses, while continued weakness among smaller U.S. spine distributors remained a headwind. The company reiterated its focus on commercial productivity, discipl

Orthofix Medical Inc. Q2 2026 Earnings Call Summary

2026-08-05
Moby summary of Orthofix Medical Inc.'s Q2 2026 earnings call

12 Health Care Stocks Moving In Wednesday's After-Market Session

2026-08-05
Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 31.4% to $0.88 during Wednesday's after-market session. The company's market cap stands at $4.2 million. Caris Life Sciences (NASDAQ:CAI)

Orthofix Medical (NASDAQ:OFIX) Jumps on Q2 Earnings Beat and Raised Guidance

2026-08-05
Orthofix Medical (OFIX) beats Q2 profit estimates, raises full-year 2026 guidance; stock up ~9.6% premarket despite in-line revenue.

Orthofix (OFIX) Q2 Earnings and Revenues Surpass Estimates

2026-08-05
Orthofix (OFIX) delivered earnings and revenue surprises of +333.33% and +0.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?